New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2013
06:25 EDTTEVA, HSP, NVS, BDXInjectable drug shortages may ease with rising interest, WSJ reports
The shortage of injectable drugs used by hospitals could ease as more healthcare companies look to become new manufacturers, Wall Street Journal reports. Becton Dickinson (BDX) became the latest player in the $7B market with yesterday's approval for an antihistamine, the paper adds. Reference Link
News For BDX;HSP;TEVA;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 11, 2016
07:01 EDTTEVATeva reports Q4 adjusted EPS $1.32, consensus $1.29
Subscribe for More Information
05:44 EDTTEVAOptions expected to be active
Subscribe for More Information
05:35 EDTNVSSandoz reports EMA acceptance of MAA for biosimilar pegfilgrastim
Sandoz, a Novartis company and the global leader in biosimilars, announced that the European Medicines Agency, or EMA, has accepted their Marketing Authorization Application, or MAA, for its biosimilar to Amgen's EU-licensed Neulasta - a long-acting recombinant human granulocyte colony-stimulating factor, or G-CSF. Sandoz is seeking approval for the same indication as the reference product.
February 10, 2016
14:32 EDTTEVANotable companies reporting before tomorrow's open
Subscribe for More Information
09:01 EDTTEVATeva volatility elevated into Q4 and outlook
Teva February weekly call option implied volatility is at 81, February is at 51, March is at 37; compared to its 52-week range of 20 to 41, suggesting large near term price movement into the expected release of Q4 results on February 11.
07:02 EDTBDXBecton Dickinson receives FDA 510(k) clearance for HIV/AIDS diagnostic device
BD has received FDA 510(k) clearance for its BD FACSPresto system and BD FACSPresto CD4/Hb Cartridge. The BD FACSPresto system is an automated multicolor fluorescent imaging cytometer and absorbance spectrometer that provides absolute and percentage results of CD4 T lymphocytes and hemoglobin concentration in whole blood samples to manage HIV/AIDS patients.
February 9, 2016
11:18 EDTNVSOptions with increasing call volume; CERS WYN NVS ZIOP PZM PI OC DB MLM
Subscribe for More Information
February 8, 2016
09:38 EDTNVSCigna enters into outcomes-based contract with Novartis
Cigna (CI) has entered into an outcomes-based contract with the pharmaceutical company Novartis (NVS) for the drug Entresto, which was approved by the FDA for the treatment of heart failure with reduced ejection fraction. The pay-for-performance agreement ties the financial terms to how well the drug improves the relative health of Cigna's customers. The primary metric is reduction in the proportion of customers with heart failure hospitalizations. This agreement is effective for Cigna's commercial business. Entresto is a preferred brand subject to prior authorization review. The prior authorization process is part of utilization management to help control prescription drug costs and ensure coverage of the most appropriate drug therapies.
09:34 EDTTEVAPfizer sees decision about potential separation by no later than end 2018
Subscribe for More Information
06:28 EDTNVSPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 7, 2016
14:27 EDTNVSNovartis' somatic cell therapy receives orphan designation
Subscribe for More Information
February 4, 2016
07:23 EDTNVSGSK will not be pressured into early consumer unit spinoff, Reuters says
Subscribe for More Information
February 3, 2016
06:14 EDTBDXBecton Dickinson backs FY16 adjusted EPS view of $8.37-$8.44, consensus $8.41
Subscribe for More Information
06:08 EDTBDXBecton Dickinson reports Q1 adjusted EPS $1.96, consensus $1.84
Reports Q1 revenue $2.99B, consensus $3.03B.
February 2, 2016
14:32 EDTBDXNotable companies reporting before tomorrow's open
Subscribe for More Information
11:14 EDTNVSNovartis management to meet with Jefferies
Subscribe for More Information
08:12 EDTTEVATeva enters into collaborative research agreement with AbCellera
Subscribe for More Information
08:01 EDTTEVATeva, AbCellera enter agreement to discover rare monoclonal antibodies
Teva and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies. Under the terms of the agreement, AbCellera will receive an upfront payment, research payments, and is eligible to receive undisclosed downstream milestones associated with the development and approval of therapeutic antibodies.
07:42 EDTNVSPressure mounts on big pharma names to shrink, sharpen focus, FT says
Subscribe for More Information
February 1, 2016
08:04 EDTTEVATeva Mylan not seeing same negative trends as Sandoz, says Bernstein
After Novartis (NVS) reported weak results for its generics unit, Sandoz, and blamed it on industry trends, Bernstein quotes Mylan (MYL) and Teva (TEVA) as saying that they are seeing only "slight adjustments back to normal levels" from "mildly favorable" results in 2014 and 2015. Bernstein says that Sandoz has lost a number of fairly profitable products and has had fewer approvals than its peers. Bernstein keeps Outperform ratings on Teva and Mylan.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use